A drug discovery company dedicated to developing treatments for Neurofibromatosis Type 1 (NF1)

iNFixion Bioscience is dedicated to developing drugs that treat and prevent the clinical manifestations of neurofibromatosis type 1 (NF1) for all patients, regardless of their specific genetic mutation. 

NF1 is caused by a mutation in one copy of the NF1 gene, leading to tumor growth on nerves throughout the body and significant neurocognitive challenges. NF1 also causes a wide range of additional manifestations including increased risk of cancer and cardiovascular disease, bone abnormalities and chronic pain and itching.

While classified as a rare disease, NF1 is one of the most common genetic disorders, affecting over 125K Americans, 250K Europeans, and 2.5M people worldwide. This provides significant market potential, supported by financial and regulatory incentives provided to rare disease therapies. 

At iNFixion, we are taking a unique approach by addressing the core disease mechanism: the lack of functional NF1 protein (neurofibromin). Our strategy enhances the body’s ability to produce and maintain healthy neurofibromin, thereby tackling the root cause of NF1.

By restoring neurofibromin function, we aim to create a transformative, disease-modifying therapy—one that not only alleviates symptoms but also prevents disease progression.

Watch our video to learn more.